A Highly Anticipated Selective Therapeutic Agent against CDK2: INX-315

Lotte P Watts; Sabrina L Spencer

doi:10.1158/2159-8290.CD-23-1537

A Highly Anticipated Selective Therapeutic Agent against CDK2: INX-315

Cancer Discov. 2024 Mar 1;14(3):386-388. doi: 10.1158/2159-8290.CD-23-1537.

Authors

Lotte P Watts¹, Sabrina L Spencer¹

Affiliation

¹ Department of Biochemistry and BioFrontiers Institute, University of Colorado-Boulder, Boulder, Colorado.

PMID: 38426558
DOI: 10.1158/2159-8290.CD-23-1537

Abstract

In this issue, Dietrich, Trub, and colleagues describe and characterize a novel selective CDK2 inhibitor: INX-315. This agent shows promise in CCNE1-amplified cancers and in CDK4/6 inhibitor-resistant breast cancers. See related article by Dietrich et al., p. 446 (8).

MeSH terms

Breast Neoplasms* / drug therapy
Breast Neoplasms* / genetics
Cyclin-Dependent Kinase 2 / genetics
Cyclin-Dependent Kinase 4 / genetics
Female
Humans

Substances

Cyclin-Dependent Kinase 2
Cyclin-Dependent Kinase 4
CDK2 protein, human